FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2620062766> ?p ?o ?g. }

• W2620062766 endingPage "627" @default.
• W2620062766 startingPage "622" @default.
• W2620062766 abstract "OBJECTIVE Our objective was to develop and validate a composite endpoint for patients with necrotizing soft tissue infections that incorporates: local tissue injury, systemic organ dysfunction, and mortality. METHODS The Necrotizing Infection Clinical Composite Endpoint (NICCE) was defined as follows:(i) alive at day 28, (ii) three or less debridements before day 14, (iii) no amputation beyond first debridement, (iv) modified sequential organ failure assessment score score (mSOFA) at day 14 ≤ 1. To be considered a success, all individual criteria must be met. Several data sets were used to assess validity: (i) a retrospective data set of 198 patients treated during 2013 at 12 US trauma centers; (ii) a subset with high disease acuity, admission mSOFA score of 3 or higher (n = 69); and (iii) 40 patients from a multicenter, phase 2 randomized trial of a CD28 immunomodulator (AB103). Clinical success based on each parameter and the composite score was assessed. RESULTS Using the retrospective data set for all patients and those with high disease severity (respectively), survival rates were 92% and 84%; day 14 mSOFA 1 or lower score was 69% and 51%; three or less debridements was 84% and 77%; and no subsequent amputations were 96% and 94%. Overall, the percent meeting all success criteria for NICCE was 58% (all patients) and 33% (mSOFA > 3). NICCE success was also associated with reduced utilization of health care resources, intensive care unit–free days were median (interquartile range) of 25.3 (21.9–28) and 19.6 (4.3–25.1) days (one-sided Wilcoxon p < 0.001) and ventilator-free days were 28 (26–28) versus 25 (14–28) (p < 0.001) for NICCE success versus failure, respectively. Using the phase 2 data set, the treated group (0.5 mg/kg, n = 15) demonstrated a NICCE success rate of 73.3% versus 40% for placebo (n = 10). CONCLUSION These data demonstrate internal consistency of the components and face and criterion validity of the NICCE endpoint. NICCE offers an opportunity to demonstrate a clinically relevant treatment effect for patients enrolled in clinical trials for necrotizing soft tissue infection. Level of Evidence Prognostic/Epidemiological, level III; Therapeutic, level IV." @default.
• W2620062766 created "2017-06-05" @default.
• W2620062766 creator A5014799818 @default.
• W2620062766 creator A5051687396 @default.
• W2620062766 creator A5058966739 @default.
• W2620062766 creator A5085685364 @default.
• W2620062766 creator A5089504452 @default.
• W2620062766 creator A5089821583 @default.
• W2620062766 date "2017-10-01" @default.
• W2620062766 modified "2023-09-24" @default.
• W2620062766 title "Validation of a clinical trial composite endpoint for patients with necrotizing soft tissue infections" @default.
• W2620062766 cites W1572450332 @default.
• W2620062766 cites W1892856590 @default.
• W2620062766 cites W1898928487 @default.
• W2620062766 cites W1974873560 @default.
• W2620062766 cites W1978532273 @default.
• W2620062766 cites W2004351784 @default.
• W2620062766 cites W2011147226 @default.
• W2620062766 cites W2014630960 @default.
• W2620062766 cites W2015218087 @default.
• W2620062766 cites W2016623562 @default.
• W2620062766 cites W2023790237 @default.
• W2620062766 cites W2026314831 @default.
• W2620062766 cites W2107256277 @default.
• W2620062766 cites W2126639715 @default.
• W2620062766 cites W2136609531 @default.
• W2620062766 cites W2149947638 @default.
• W2620062766 cites W2153589783 @default.
• W2620062766 cites W2162851579 @default.
• W2620062766 cites W2168739217 @default.
• W2620062766 cites W2237700736 @default.
• W2620062766 cites W2280404143 @default.
• W2620062766 cites W2316103117 @default.
• W2620062766 cites W4376595806 @default.
• W2620062766 doi "https://doi.org/10.1097/ta.0000000000001564" @default.
• W2620062766 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/28538644" @default.
• W2620062766 hasPublicationYear "2017" @default.
• W2620062766 type Work @default.
• W2620062766 sameAs 2620062766 @default.
• W2620062766 citedByCount "13" @default.
• W2620062766 countsByYear W26200627662018 @default.
• W2620062766 countsByYear W26200627662019 @default.
• W2620062766 countsByYear W26200627662020 @default.
• W2620062766 countsByYear W26200627662021 @default.
• W2620062766 countsByYear W26200627662022 @default.
• W2620062766 crossrefType "journal-article" @default.
• W2620062766 hasAuthorship W2620062766A5014799818 @default.
• W2620062766 hasAuthorship W2620062766A5051687396 @default.
• W2620062766 hasAuthorship W2620062766A5058966739 @default.
• W2620062766 hasAuthorship W2620062766A5085685364 @default.
• W2620062766 hasAuthorship W2620062766A5089504452 @default.
• W2620062766 hasAuthorship W2620062766A5089821583 @default.
• W2620062766 hasConcept C119060515 @default.
• W2620062766 hasConcept C126322002 @default.
• W2620062766 hasConcept C136948725 @default.
• W2620062766 hasConcept C141071460 @default.
• W2620062766 hasConcept C167135981 @default.
• W2620062766 hasConcept C168563851 @default.
• W2620062766 hasConcept C203092338 @default.
• W2620062766 hasConcept C2776204877 @default.
• W2620062766 hasConcept C2776376669 @default.
• W2620062766 hasConcept C535046627 @default.
• W2620062766 hasConcept C71924100 @default.
• W2620062766 hasConceptScore W2620062766C119060515 @default.
• W2620062766 hasConceptScore W2620062766C126322002 @default.
• W2620062766 hasConceptScore W2620062766C136948725 @default.
• W2620062766 hasConceptScore W2620062766C141071460 @default.
• W2620062766 hasConceptScore W2620062766C167135981 @default.
• W2620062766 hasConceptScore W2620062766C168563851 @default.
• W2620062766 hasConceptScore W2620062766C203092338 @default.
• W2620062766 hasConceptScore W2620062766C2776204877 @default.
• W2620062766 hasConceptScore W2620062766C2776376669 @default.
• W2620062766 hasConceptScore W2620062766C535046627 @default.
• W2620062766 hasConceptScore W2620062766C71924100 @default.
• W2620062766 hasIssue "4" @default.
• W2620062766 hasLocation W26200627661 @default.
• W2620062766 hasLocation W26200627662 @default.
• W2620062766 hasOpenAccess W2620062766 @default.
• W2620062766 hasPrimaryLocation W26200627661 @default.
• W2620062766 hasRelatedWork W2042549362 @default.
• W2620062766 hasRelatedWork W2047967234 @default.
• W2620062766 hasRelatedWork W2061253854 @default.
• W2620062766 hasRelatedWork W2067062555 @default.
• W2620062766 hasRelatedWork W2383404606 @default.
• W2620062766 hasRelatedWork W2439875401 @default.
• W2620062766 hasRelatedWork W4205090442 @default.
• W2620062766 hasRelatedWork W4252075551 @default.
• W2620062766 hasRelatedWork W4304166187 @default.
• W2620062766 hasRelatedWork W3030510653 @default.
• W2620062766 hasVolume "83" @default.
• W2620062766 isParatext "false" @default.
• W2620062766 isRetracted "false" @default.
• W2620062766 magId "2620062766" @default.
• W2620062766 workType "article" @default.